The recent announcement dated today: "Endeavour Reports Q2 All-In Sustaining Cost of $1,038/oz(PDF "
Seems like a well presented document, with no bs - just the straight out numbers. I like the way they report all in, similar to what NST has been going on about. I am, however, perplexed by the share price and where we are at relative to say NST. We seem to have comparative ~$1,000 all in costs.
So my question is, in a bid to work out our pricing differential, short of the actual price-in of exploration upside that NST undoubtedly have (then again we have new mines in the form of Agabou coming on board soon) - what is causing our lack of a rerating?
So my thoughts are: debt. My next question is, given I'm at work and don't have time to analyse the above announcement - does the all in costs of $1,038 which include 'Corporate - G & A' include interest costs on the debt?
Table 5 clearly shows interest of $1.6million, but I am wondering where this fits in in line with our $1,038 all in costs. Has anyone worked it out if it's included?
I note the $200 million corporate facility has been drawn down already (and the incremental part by july), with over 80% of capital costs/construction done at agabou. So I'm wonder if $1.6million interest for the quarter sounds about right... or if it was due to the corporate facility only being recently drawn, so we should see interest rising a few million shortly?
Haven't dug through old announcements but has a % interest rate been stated on the facility so we can estimate finance costs?
- Forums
- ASX - By Stock
- EVR
- all in sustaining cost
EVR
ev resources ltd
Add to My Watchlist
11.1%
!
0.8¢

all in sustaining cost
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $15.88M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.8¢ | $12.78K | 1.525M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 116245 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 3146644 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 116245 | 0.008 |
11 | 10916761 | 0.007 |
6 | 16200000 | 0.006 |
7 | 4287033 | 0.005 |
15 | 3574221 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1896644 | 6 |
0.010 | 2129565 | 5 |
0.011 | 1184641 | 5 |
0.012 | 550000 | 3 |
0.014 | 319427 | 3 |
Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
Featured News
EVR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online